ストックスクリーナーアプリを入手
0.9963
5.11%
-0.0537
アフターアワーズ：
1.01
0.0137
+1.38%
Adc Therapeutics Sa (ADCT) 最新ニュース
Bronstein, Gewirtz & Grossman, LLC Encourages ADC Therapeutics SA (ADCT) Stockholders to Inquire about Securities Investigation - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Aga - The National Law Review
2026-06-14 | Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against ADC Therapeutics SA (ADCT) and Encourages Investors to Learn More About the Investigation | NYSE:ADCT | Press Release - Stockhouse
Are medical stocks lagging ADC Therapeutics (ADCT) this year? - MSN
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against ADC Therapeutics SA (ADCT) And Encourages Investors to Reach Out - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against ADC Therapeutics SA (ADCT) And Encourages Stockholders to Reach Out - ACCESS Newswire
ADC Therapeutics SA (ADCT) reports Q1 loss, beats revenue estimates - MSN
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADC Therapeutics SAADCT - PR Newswire
Bronstein, Gewirtz & Grossman, LLC Is Investigating ADC Therapeutics SA (ADCT) And Encourages Stockholders to Connect - ACCESS Newswire
symbol__ Stock Quote Price and Forecast - CNN
ADC Therapeutics SA (ADCT) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
ADC Therapeutics SA (ADCT) Investigation: Bronstein, Gewirtz & Gr - The National Law Review
ADC Therapeutics falls on confirmatory trial data for lymphoma therapy - MSN
ADCT Downgraded by HC Wainwright & Co. -- Rating Changed to Neut - GuruFocus
ADC Therapeutics SA (ADCT) Discusses Phase III LOTIS-5 Trial Results and Next Steps in DLBCLSlideshow - Seeking Alpha
ADC Therapeutics Shares Fall After HC Wainwright Downgrade - marketscreener.com
This ADC Therapeutics Analyst Is No Longer Bullish; Here Are Top 2 Downgrades For Monday - Benzinga
ADC Therapeutics (ADCT) Is Down 69.7% After Mixed LOTIS-5 ZYNLONTA DataHas The Bull Case Changed? - Yahoo Finance
ADC Therapeutics Tumbles On Phase 3 Trial Safety Concerns, Joins Other Big Stocks Moving Lower In Thursda - Benzinga
ADC Therapeutics: 'Sell' LOTIS-5 Underwhelms And Possible Change In Strategy (NYSE:ADCT) - Seeking Alpha
ADC Therapeutics SA (ADCT) Stock Price, Quote, News & History - Benzinga
Why Is ADC Therapeutics Stock Falling On Friday?ADC Therapeutics (NYSE:ADCT) - Benzinga
Why Is ADC Therapeutics Stock Falling Thursday? - Sahm
ADC Therapeutics’ Zynlonta Clears Phase III PFS Bar But Safety Concerns Cloud FDA Path - Citeline News & Insights
ADCT stock plunges on safety concerns despite positive lymphoma data - MSN
ADCT Downgraded by RBC Capital -- Price Target Lowered to $2.00 - GuruFocus
Zynlonta Lotis position in DLBCL strains ADC shares - BioWorld News
ADCT Stock Plunges on Safety Concerns Despite Positive Lymphoma Data - Yahoo Finance
ADC Therapeutics plunges after patient deaths in blood cancer drug trial - Reuters
ADC Thera falls on trial data for lymphoma drug (ADCT:NYSE) - Seeking Alpha
RBC Downgrades ADC Therapeutics to Sector Perform From Outperform, Cuts Price Target to $2 From $6, Keeps Speculative Risk - marketscreener.com
An ADC specialist sinks on safety concerns for blood cancer drug - Yahoo Finance
RBC Capital cuts ADC Therapeutics stock rating on trial results By Investing.com - Investing.com UK
ADC Therapeutics stock plunges on trial safety concerns By Investing.com - Investing.com Australia
ADC Therapeutics Announces Results From LOTIS-5 Phase 3 Confirma - GuruFocus
ADC Therapeutics Announces Results From LOTIS-5 Phase 3 Confirmatory Clinical Trial of ZYNLONTA® in Combination with Rituximab in Relapsed or Refractory Diffuse Large B-Cell Lymphoma - BioSpace
Has ADC Therapeutics' ZYNLONTA Delivered on its Phase 3 Promise - Kavout
ADC Therapeutics stock plunges on trial safety concerns - Investing.com
ADC Therapeutics reports positive phase 3 trial results By Investing.com - Investing.com India
ADC Therapeutics reports positive phase 3 trial results - Investing.com
ADCT: LOTIS-5 met its PFS endpoint, with durable CRs but higher Grade 5 events in elderly patients - TradingView
ADCT: LOTIS-5 met its primary PFS endpoint, with Lonca-R showing higher CR rates than R-GemOx - TradingView
ADC Therapeutics' Drug Regimen to Treat B-Cell Lymphoma Meets Primary Endpoint of Progression-Free Survival in Phase 3 Trial - marketscreener.com
12 Health Care Stocks Moving In Wednesday's After-Market Session - Benzinga
ADC Therapeutics (NYSE: ADCT) director gets 45K RSUs, 12.6K shares withheld - Stock Titan
ADC Therapeutics (ADCT) director receives RSU award and shares withheld for taxes - Stock Titan
ADC Therapeutics (ADCT) director logs RSU grant and tax withholding on Form 4 - Stock Titan
ADC Therapeutics (ADCT) director granted 45K RSUs, 2.6K shares withheld - Stock Titan
ADC Therapeutics (ADCT) director receives 45,000 RSUs and 2,156-share tax withholding - Stock Titan
ADC Therapeutics (ADCT) director RSU grant and 12,600-share tax withholding - Stock Titan
ADC Therapeutics (NYSE: ADCT) director gets RSU grant and tax withholding - Stock Titan
Swedish Orphan Biovitrum : ADC Therapeutics announces results from LOTIS-5 Phase 3 confirmatory clinical trial - marketscreener.com
ADC Therapeutics reports positive LOTIS-5 PFS results; plans pre-sBLA meeting and Q4 2026 sBLA - TradingView
LOTIS-5 trial: ADC Therapeutics (NYSE: ADCT) shows PFS gain but higher toxicity - Stock Titan
1.27%
1.43%
大文字化:
|
ボリューム (24 時間):